Related Experiment Video
Updated: May 20, 2026

Radiation Planning Assistant - A Web-based Tool to Support High-quality Radiotherapy in Clinics with Limited Resources
Published on: October 6, 2023
The evolving PI-RADS paradigm
Andrea Ponsiglione1, Ivo G Schoots2,3, Anwar R Padhani4
1Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.
Abstract:
Prostate MRI is central to the diagnostic pathway for prostate cancer (PCa), reducing unnecessary biopsies, improving the detection of clinically significant disease (csPCa), and limiting overdiagnosis of indolent tumours. The Prostate Imaging Reporting and Data System (PIRADS) version 2.1 is the current international standard for MRI data acquisition and interpretation. This review synthesises the evidence for its use, its strengths and limitations, and future developments. PI-RADS v2.1 improved the assessments of multiparametric MRI (mpMRI) by clarifying technical requirements, zone-specific interpretation rules, and structured reporting recommendations. Its diagnostic performance is well established, particularly for ruling out csPCa and guiding risk-adapted biopsy strategies. However, significant gaps remain. MRI image quality varies substantially across centres, and PI-RADS lacks a mechanism to exclude non-diagnostic scans, resulting in inconsistent classification. Several scoring challenges persist, most notably the ambiguous definition and heterogeneous management of PI-RADS 3 lesions, imprecise lesion measurement standards, and limited guidance for central-zone and atypical lesions. Gaps include the absence of strategies for assessing background tissue changes and infiltrative patterns. Cancer detection specificity and inter-reader agreement remain moderate, with significant discrepancies in transition-zone assessments. Artificial intelligence (AI) holds promise for reducing variability, improving lesion detection, and optimising workflow, though rigorous validation and clear human-AI integration frameworks are needed. Advances in deep learning reconstructions improve image quality and enable shorter protocols, thereby supporting the adoption of biparametric MRI. A shift toward risk-based pathways, integrating MRI findings with PSA density and clinical parameters, is reflected in the forthcoming PI-RADS Pathway 2026, which aims to standardize global biopsy practice and reduce unnecessary interventions.
Insights
Prostate MRI, guided by PI-RADS v2.1, enhances prostate cancer diagnosis but faces challenges in image quality and lesion assessment. Future developments, including AI and risk-based pathways, aim to improve accuracy and reduce unnecessary biopsies.
Area of Science:
- Radiology and Medical Imaging
- Oncology
- Diagnostic Medicine
Background:
- Prostate MRI is crucial for diagnosing prostate cancer (PCa), aiding in biopsy decisions and reducing overdiagnosis.
- The Prostate Imaging Reporting and Data System (PI-RADS) v2.1 is the current international standard for prostate MRI acquisition and interpretation.
- PI-RADS v2.1 enhanced multiparametric MRI (mpMRI) assessments with clearer technical requirements and reporting.
Purpose of the Study:
- To review the evidence supporting PI-RADS v2.1 use in prostate cancer diagnosis.
- To identify the strengths, limitations, and future directions of PI-RADS v2.1.
- To explore the potential of artificial intelligence (AI) and evolving pathways in prostate MRI interpretation.
Main Methods:
- Literature review synthesizing evidence on PI-RADS v2.1.
- Analysis of diagnostic performance, particularly in ruling out clinically significant PCa (csPCa).
- Evaluation of current challenges, including image quality variability, PI-RADS 3 lesion management, and inter-reader agreement.
Main Results:
- PI-RADS v2.1 demonstrates good diagnostic performance for csPCa detection and risk-adapted biopsies.
- Significant limitations persist, including inconsistent image quality, challenges with PI-RADS 3 lesions, and moderate specificity/inter-reader agreement.
- Artificial intelligence (AI) shows promise for improving lesion detection and workflow, while advances support biparametric MRI adoption.
Conclusions:
- Despite improvements, PI-RADS v2.1 has limitations requiring further development for consistent prostate cancer assessment.
- Future directions involve integrating AI, refining risk-based pathways (e.g., PI-RADS Pathway 2026), and standardizing global biopsy practices.
- The goal is to enhance diagnostic accuracy, reduce unnecessary interventions, and improve patient outcomes in prostate cancer management.
More Related Videos
08:01Rapid Scan Electron Paramagnetic Resonance Opens New Avenues for Imaging Physiologically Important Parameters In Vivo
Published on: September 26, 2016
07:57Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
Published on: March 24, 2022
Related Concept Videos
Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
Radiological Investigation III: Pulmonary Angiogram and PET Scan
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
Methods of Documentation III: PIE